d09cad5a1cf2807b079f24b41220cde2

EQUIPO HIBRIDO SPECT-CT SYMBIA/ SPECT CT

SIEMENS HEALTHCARE S.A.S.·IIb·Colombia INVIMA·Expires July 30, 2029
Device classification
Risk class / Clase de Riesgo
IIb
Product type (Spanish)
MEDICO QUIRURGICOS
Product type (English)
SURGICAL DOCTOR
Registration information
Analysis ID
d09cad5a1cf2807b079f24b41220cde2
Expire date
July 30, 2029
Authorized company / Fabricante
Name (English)
SIEMENS HEALTHCARE S.A.S.
Product use / Uso del Producto
Spanish

SISTEMA DE ADQUISICION DE IMAGENES QUE REALIZA UN ESTUDIO MEDINATE LA FUSION DE TOMOGRAFIA COMPUTARIZADA E IMAGENOLOGIA NUCLEAR. LA INTEGRACION DEL SPECT Y DEL CT DE DIVERSOS CORTES DE ALTA CALIDAD, SEGÚN EL MODELO, PROPORCIONAN A ESTE SISTEMA UNA FUNCIONALIDAD COMPLETA PARA TODAS LAS APLICACIONES DE DIAGNÓSTICO DE SPECT UNICAMENTE, SPECT-CT O CT INDEPENDIENTEMENTE EN ONCOLOGÍA, NEUROLOGÍA Y CARIOLOGÍA RUTINARIA.

English

IMAGE ACQUISITION SYSTEM THAT PERFORMS A MEDINATE STUDY THE FUSION OF COMPUTED TOMOGRAPHY AND NUCLEAR IMAGING. THE INTEGRATION OF SPECT AND CT SCANS OF VARIOUS HIGH-QUALITY SLICES, DEPENDING ON THE MODEL, PROVIDES THIS SYSTEM WITH COMPLETE FUNCTIONALITY FOR ALL SPECT DIAGNOSTIC APPLICATIONS ONLY, SPECT-CT OR CT INDEPENDENTLY IN ONCOLOGY, NEUROLOGY AND ROUTINE CARIOLOGY.

About this record

Access comprehensive regulatory information for EQUIPO HIBRIDO SPECT-CT SYMBIA/ SPECT CT (EQUIPO HIBRIDO SPECT-CT SYMBIA/ SPECT CT) in the Colombia medical device market through Pure Global AI's free database. This IIb medical device is registered under INVIMA analysis ID d09cad5a1cf2807b079f24b41220cde2 and manufactured by SIEMENS HEALTHCARE S.A.S.. The device was registered on July 30, 2029.

This page provides complete registration details including product type (SURGICAL DOCTOR), authorised information, and regulatory compliance data from the official Colombia INVIMA medical device database. Pure Global AI offers free access to Colombia's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate INVIMA regulations efficiently.